- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03185650
Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device
Evaluation of Regional Lung Deposition of Inhaled Saline Using the Trans-Nasal Pulmonary Aerosol Delivery Device in Healthy, Non-Smoking Adult Subjects
Purpose: Characterize the depositional attributes of a specialized trans-nasal aerosol delivery device in healthy people using clinical measurements of mucociliary clearance.
Procedures (methods): 14% hypertonic saline (HS) aerosol containing the radio tracer Tc99m-sulfur colloid will be delivered via the tPAD and compared to the well characterized PARI LC Star nebulizer (7% HS) using planar gamma scintigraphy (i.e. particle clearance). The fraction of sulfur colloid particles that clear over the ensuing 24 hours with each device will indicate the fraction deposited in conducting airways.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose: This is an early device characterization study to define the fraction of delivered aerosol generated by a novel nebulizer (tPAD) that deposits in conducting airways.
Design: Open label, cross-over design, using a standard oral nebulizer (PARI LC Star) as a comparator. The order of visits will be randomized.
Methods: Gamma scintigraphy will be performed following use of each device on separate study visits.
Primary Outcome: Fraction of inhaled particles that clears over 24 hours.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina At Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged 18 to 65 years (inclusive), and with a body mass index (BMI) < 30 kg/m2.
- Non-pregnant female subjects must be either not sexually active, post-menopausal, surgically sterilized, or agree to use an appropriate "double-barrier" method (such as a diaphragm and condom); or, must currently be using a prescribed transdermal, injection, implant, or oral contraceptive during study participation.
- Subjects who are in good health, as determined by a medical history and examination.
- Subjects who have normal lung function with a FEV1 ≥80% predicted and a FEV1/FVC >70%.
- Subjects who are capable of providing written informed consent in English to participate in the study.
Exclusion Criteria:
- Subjects who have evidence of an upper or lower respiratory infection or clinically significant illness at entry or within 14 days of the start of dosing.
- Subjects with lung diseases as defined by a FEV1 <80% or a FEV1/FVC <70%
- Subjects on inhaled medications, such as short or long acting bronchodilators or inhaled corticosteroids, will be excluded.
- Subjects with a history of allergy or intolerance to albuterol or hypertonic saline.
- Subjects with active chronic or acute rhinosinusitis or other nasal or sinus abnormality or disease.
- Subjects who have a present history of any clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological disorder or disease, substance abuse, or any other major disorder or disease.
- Subjects who have had radiation exposure within the past year that would cause them to exceed Federal Regulations of 15 Rem annually by participating in this study. The study team will determine this.
- Subjects with a history of smoking within the last 3 months.
- Subjects with a positive pregnancy test or who are pregnant or are nursing.
- Subjects who, in the opinion of the Principal Investigator, should not participate in the study.
- Subjects with a BMI >30 kg/m2
- Subjects who are taller than Height >6'2"
- Subjects who have facial hair that they are not willing to shave
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: tPAD, then PARI LC Star Nebulizer
tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
|
A novel, transnasal aerosol generator
Standard oral nebulizer
|
Other: PARI LC Star Nebulizer, then tPAD
PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
|
A novel, transnasal aerosol generator
Standard oral nebulizer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
24-hour clearance fraction
Time Frame: 24 hours
|
The percentage of initially deposited aerosol particles that clear over 24 hours will be measured with gamma scintigraphy after 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central:Peripheral Deposition Ratio
Time Frame: 0-4 minutes after deposition
|
The ratio of labelled particles initially deposited in the central and peripheral lung zones will be assessed to characterize aerosol targeting of the lung
|
0-4 minutes after deposition
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-2124
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Diseases
-
Aveiro UniversityFundação para a Ciência e a TecnologiaNot yet recruitingInterstitial Lung DiseasesPortugal
-
RWTH Aachen UniversityCompletedObstructive Lung DiseasesGermany
-
Guangzhou Institute of Respiratory DiseaseUnknownInterstitial Lung Disease | Transbronchial Lung Cryobiopsy | Surgical Lung Biopsy
-
China-Japan Friendship HospitalXiangya Hospital of Central South University; Peking Union Medical College... and other collaboratorsUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedInterstitial Lung DiseasesNetherlands
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
Shanghai East HospitalRegend TherapeuticsCompletedInterstitial Lung DiseasesChina
-
Aveiro UniversityFundação para a Ciência e a Tecnologia; Centro Hospitalar do Baixo VougaRecruitingInterstitial Lung Diseases (ILD)Portugal
-
China-Japan Friendship HospitalNot yet recruitingTransbronchial Lung Cryobiopsy
Clinical Trials on tPAD Device
-
Altec Inc.Columbia UniversityCompletedCerebral Palsy | Gait Disorders, NeurologicUnited States
-
Stanford UniversityTauTona GroupEnrolling by invitationLaparoscopic SurgeryUnited States
-
Columbia UniversityCompleted
-
Stanford UniversityTauTona GroupEnrolling by invitation
-
University of North Carolina, Chapel HillWithdrawnCOPD | Chronic BronchitisUnited States
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
Karolinska InstitutetUnknownDegenerative Disc Disease | Discogenic Low Back PainSweden
-
Cala Health, Inc.Not yet recruiting
-
AOTI Ltd.UnknownDiabetic Foot UlcerUnited Kingdom, United States, Germany, France, Luxembourg
-
International Agency for Research on CancerUniversity of North Carolina Global Project Zambia; Liger Medical LlcCompleted